MiNK TherapeuticsINKT
INKT
$0.7500
2.22%
Market Cap: $29.7M
About: MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.
Employees: 37
0
Funds holding %
of 6,710 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0% less capital invested
Capital invested by funds: $849K [Q1] → $848K (-$823) [Q2]
0.11% less ownership
Funds ownership: 2.7% [Q1] → 2.59% (-0.11%) [Q2]
9% less funds holding
Funds holding: 34 [Q1] → 31 (-3) [Q2]
30% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 10
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$9
1,100%
upside
Avg. target
$9
1,100%
upside
High target
$9
1,100%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Emily Bodnar 35% 1-year accuracy 17 / 49 met price target | 1,100%upside $9 | Buy Reiterated | 13 Aug 2024 |